Plum Bio 3.822 billion buy Sipin biological, said the industry reshuffle is nearing the end

listed company, Meihua Bio, which has been suspended since August, has announced plans to sell a 100 percent stake in Ningxia Yipin Bio for $3,822 million, which will resume trading on November 17Wen Tingyi, a researcher at the Institute of Microbiology of the Chinese Academy of Sciences, said that after the plum blossoms join forces with Eipin, it will be a "big plum", with its share of amino acid sales reaching 80% of the country and 50% of the world's totalaDZ
Meng Qingshan, chairman of Meihua Bio, said that China's amino acid industry in previous years the production capacity expanded but the competition disorder, "brother-to-brother" delayed innovation, "internal consumption" is unsustainable"China's amino acid industry has been hovering in the trough for three years, the industry reshuffle has come to an end, small businesses are basically out, the rest are excellent enterprises, next year's second quarter will come up." The partnership between Plum and Epin can help the industry get out of winter early"For example, after Meihua bought Eminem, the price of a ton of susine rose from 10,000 to 30,000aDZ
According to Yiping Bio Chairman Ni Xiaoping, the company's amino acid income accounted for about 45% of the total sales of Ispin biological, market share in the domestic market accounted for about 75%, of which 25% for export, but currently relatively short of money, through the introduction of plum biology can increase investment in research and developmentaDZ
Plum Bio Chairman: Brotherly and disabled after more than two months of suspension of theaDZ, on November 15, Meihua Bio announced that it intends to pay 3.822 billion to Ningxia Yipin Biotech Co., Ltd("Ipin Bio") all shareholders of the non-public issue of shares and pay cash to purchase its total holding of 100% of the shares of Ipin Bio shares on November 17, 2014aDZ
Public data show that the total assets of plum biology has reached 19.7 billion yuanData show that the first three quarters of meihua bio revenue was 7.277 billion, up 24.28 percent year-on-year, while shareholder stake attributable to listed companies was 271 million, down 1.3 percent year-on-yearaDZ
Meihua Bio Chairman Meng Qingshan said that China's amino acid industry and foreign counterparts such as South Korea's Hijie compared to a large gap, in previous years the expansion of production capacity but the competition disorder, "brotherly fratricidal" delayed innovation and environmental management, "internal consumption" is unsustainable"The next step is for our brothers to innovate together, not to say that after the market share increases, we will raise the price." Meng Qingshan also revealed that the next step, plum biology will be from raw material stoices to directly face the market, and enter the internationalaDZ
Meng Qingshan said, "China's amino acid industry has been hovering in the trough for three years, the industry reshuffle has come to an end, small businesses are basically out, the rest are excellent enterprises, next year's second quarter will come up." The partnership between Plum and Epin can help the industry get out of winter early"For example, after Meihua bought Eminem, the price of a ton of susine rose from 10,000 to 30,000aDZ
Meng Qingshan pointed out that Ipin's high debt is largely due to the high interest financing costs, and with the listed company's guarantee, Ipin's financing costs will fallaDZ
　　According to Yiping Bio Chairman Zhai Xiaoping, the company's amino acid income accounted for about 45% of the total sales of Ispin biological products, accounting for 75% of the domestic market share, of which 25% is for export, but currently relatively short of money, through the introduction of plum biology can increase investment in research and development aDZ
　　After more than a year of shuffling, prices are nearing bottom and starting to rise, and dealers are starting to go from zero to inventory, with sales of 320 million in October and a profit of 36 million, Mr Zou said After several years of investment in science and technology research and development, The per capita production efficiency of Ipin is 30% higher than that of its domestic counterparts Zhai Xiaoping said that in the industry-adjusted environment, through strong merger, research and development sales capacity will be more powerful aDZ
　　Shi Weichen, chairman of the China Biofermentation Industry Association, said that in recent years, the amino acid industry is facing the slow development rate, the proportion of low-end products is too high, the industry profit decline and other issues, the cooperation between Plum Biology and Ispin bio will make a demonstration of the future industry integration, industrial integration is the trend of the amino acid industry aDZ
　　Wen Tingyi, a researcher at the Institute of Microbiology of the Chinese Academy of Sciences, said that after the plum blossoms join forces with Eipin, it will be a "big plum", with its share of amino acid sales reaching 80% of the country and 50% of the world's total aDZ
　　The link behind the merger: Zhongzhi Capital aDZ today, Meihua Bio held a press conference to show that the merger dust landed It is worth noting that Zhongzhi Capital made a high-profile appearance at the meeting According to Sina Finance, the leader behind the merger is Zhongzhi Capital It is reported that in 2013, in the amino acid market as a whole weak environment, Zhongzhi Capital invested 500 million yuan to become a strategic investor in Ipin bio, and then assisted and actively promoted the strong combination with plum biology aDZ
　　Wang Wei, president of Zhongzhi Capital Group, said that the cooperation between Meihua Bio and Ipin Bio will produce a world-class leader in the MSG industry, greatly improving the ability to resist risks aDZ
　　Chen Xiaosheng, director of Shenyin Wanguo, said that by September this year, the number of mergers and acquisitions by Listed Companies in China had reached 1 trillion yuan, more than in all of 2013 He predicted that financing costs will fall in 2015, capital market mergers and acquisitions will become more active, capital structure changes will promote changes in industrial structure aDZ since August, the listed company Meihua Bio announced plans to pay 3.822 billion to Ningxia Yipin Bio 100% of the shares, the company will start to resume trading on November 17 Wen Tingyi, a researcher at the Institute of Microbiology of the Chinese Academy of Sciences, said that after the plum blossoms join forces with Eipin, it will be a "big plum", with its share of amino acid sales reaching 80% of the country and 50% of the world's total aDZ
　　Meng Qingshan, chairman of Meihua Bio, said that China's amino acid industry in previous years the production capacity expanded but the competition disorder, "brother-to-brother" delayed innovation, "internal consumption" is unsustainable "China's amino acid industry has been hovering in the trough for three years, the industry reshuffle has come to an end, small businesses are basically out, the rest are excellent enterprises, next year's second quarter will come up." The partnership between Plum and Epin can help the industry get out of winter early "For example, after Meihua bought Eminem, the price of a ton of susine rose from 10,000 to 30,000 aDZ
　　According to Yiping Bio Chairman Ni Xiaoping, the company's amino acid income accounted for about 45% of the total sales of Ispin biological, market share in the domestic market accounted for about 75%, of which 25% for export, but currently relatively short of money, through the introduction of plum biology can increase investment in research and development aDZ
　　Plum Bio Chairman: Brotherly and disabled after more than two months of suspension of the aDZ , on November 15, Meihua Bio announced that it intends to pay 3.822 billion to Ningxia Yipin Biotech Co., Ltd ("Ipin Bio") all shareholders of the non-public issue of shares and pay cash to purchase its total holding of 100% of the shares of Ipin Bio shares on November 17, 2014 aDZ
　　Public data show that the total assets of plum biology has reached 19.7 billion yuan Data show that the first three quarters of meihua bio revenue was 7.277 billion, up 24.28 percent year-on-year, while shareholder stake attributable to listed companies was 271 million, down 1.3 percent year-on-year aDZ
　　Meihua Bio Chairman Meng Qingshan said that China's amino acid industry and foreign counterparts such as South Korea's Hijie compared to a large gap, in previous years the expansion of production capacity but the competition disorder, "brotherly fratricidal" delayed innovation and environmental management, "internal consumption" is unsustainable "The next step is for our brothers to innovate together, not to say that after the market share increases, we will raise the price." Meng Qingshan also revealed that the next step, plum biology will be from raw material stoices to directly face the market, and enter the international aDZ
　　Meng Qingshan said, "China's amino acid industry has been hovering in the trough for three years, the industry reshuffle has come to an end, small businesses are basically out, the rest are excellent enterprises, next year's second quarter will come up." The partnership between Plum and Epin can help the industry get out of winter early "For example, after Meihua bought Eminem, the price of a ton of susine rose from 10,000 to 30,000 aDZ
　　Meng Qingshan pointed out that Ipin's high debt is largely due to the high interest financing costs, and with the listed company's guarantee, Ipin's financing costs will fall aDZ
　　According to Yiping Bio Chairman Zhai Xiaoping, the company's amino acid income accounted for about 45% of the total sales of Ispin biological products, accounting for 75% of the domestic market share, of which 25% is for export, but currently relatively short of money, through the introduction of plum biology can increase investment in research and development aDZ
　　After more than a year of shuffling, prices are nearing bottom and starting to rise, and dealers are starting to go from zero to inventory, with sales of 320 million in October and a profit of 36 million, Mr Zou said After several years of investment in science and technology research and development, The per capita production efficiency of Ipin is 30% higher than that of its domestic counterparts Zhai Xiaoping said that in the industry-adjusted environment, through strong merger, research and development sales capacity will be more powerful aDZ
　　Shi Weichen, chairman of the China Biofermentation Industry Association, said that in recent years, the amino acid industry is facing the slow development rate, the proportion of low-end products is too high, the industry profit decline and other issues, the cooperation between Plum Biology and Ispin bio will make a demonstration of the future industry integration, industrial integration is the trend of the amino acid industry aDZ
　　Wen Tingyi, a researcher at the Institute of Microbiology of the Chinese Academy of Sciences, said that after the plum blossoms join forces with Eipin, it will be a "big plum", with its share of amino acid sales reaching 80% of the country and 50% of the world's total aDZ
　　The link behind the merger: Zhongzhi Capital aDZ today, Meihua Bio held a press conference to show that the merger dust landed It is worth noting that Zhongzhi Capital made a high-profile appearance at the meeting According to Sina Finance, the leader behind the merger is Zhongzhi Capital It is reported that in 2013, in the amino acid market as a whole weak environment, Zhongzhi Capital invested 500 million yuan to become a strategic investor in Ipin bio, and then assisted and actively promoted the strong combination with plum biology aDZ
　　Wang Wei, president of Zhongzhi Capital Group, said that the cooperation between Meihua Bio and Ipin Bio will produce a world-class leader in the MSG industry, greatly improving the ability to resist risks aDZ
　　Chen Xiaosheng, director of Shenyin Wanguo, said that by September this year, the number of mergers and acquisitions by Listed Companies in China had reached 1 trillion yuan, more than in all of 2013 He predicted that financing costs will fall in 2015, capital market mergers and acquisitions will become more active, capital structure changes will promote changes in industrial structure aDZ
Share it on feed